{"schema":"sb.node.v1","id":"sb:e/742d7293af168534ed95ef53","kind":"entity","label":{"text":"her2-negative","locale":"en"},"identity":{"anchor":"label:en:her2-negative","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T15:54:56.699691+00:00","snapshot":"deploy 5dd6bfa537b0d111fd487bdb898acfd5f7a13cfd"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":44,"separatePublishers":13,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.583,"named":7,"of":12,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-23","to":"2026-10-06","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.477: about 52% of mentions carry no typed assertion"]}},"dimensions":{"domains":["precision_medicine","society_news","fda_decisions"],"activeDays":23,"assertions":{"regulatory-approval":18,"utterance":1,"launch-release":1,"election":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":7,"byKind":{"observation":7},"withheld":{"state":"withheld","count":5,"offTopic":5,"reason":"5 receipts not served: 5 off topic: the receipt's own headline does not name the subject (the document mentions it elsewhere, so it is counted in standing.evidence.supporting, but it is not a receipt about the subject)"},"items":[{"id":"sb:o/029b3d60d0ceab7c4d7a4e88","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-06 · Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translatio…","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1918231"},{"id":"sb:o/fc911f2d94350194e91490b5","kind":"observation","label":"FDA D.I.S.C.O. (Drug Info Soundcast in Clinical · 2026-09-18 · FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast can…","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or"},{"id":"sb:o/a04e02dcf889816a6eb6416b","kind":"observation","label":"Annals of Oncology · 2026-09-09 · Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the Oly…","url":"https://www.sciencedirect.com/science/article/pii/S0923753426014560?dgcid=rss_sd_all"},{"id":"sb:o/0321b8198fa1750619fcc1ff","kind":"observation","label":"FDA · 2026-09-05 · FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"},{"id":"sb:o/4ea5543b0947275c285b0e96","kind":"observation","label":"The ASCO Post · 2026-09-04 · Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy","url":"https://ascopost.com/issues/august-25-2026/phase-iii-optima-trial-many-patients-with-er-positive-her2-negative-breast-cancer-may-be-able-to-avoid-chemotherapy/"},{"id":"sb:o/e6455aceda3d6c976f74001f","kind":"observation","label":"FDA Drug News · 2026-07-15 · [APPROVAL] FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally"},{"id":"sb:o/3a423a59ed262bbe2949c87f","kind":"observation","label":"FDA Drug News · 2026-05-03 · [APPROVAL] FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","url":"http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast"}],"cursor":null,"order":"newest first; we keep the 7 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":{"state":"cannot-measure","reason":"claims: this subject's maintained record could not be read (the maintained record \"her2-negative\" could not measure its claims: this subject was retired from the publication registry on 2026-09-30 (no longer clears the admission conditions — re-checked 2026-09-30 (no receipt in the corpus-evidence shard for this label)); the record is kept as a dated tombstone and is no longer maintained). The items listed come from the passes that could be read"},"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with her2 (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5ffcb60758915053566fb54f"},{"kind":"relation","label":"co-mentioned with breast cancer (40 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4bcdf50d43e01ab3aae8b148"},{"kind":"relation","label":"co-mentioned with fda (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/227640c1d3509456ee201457"},{"kind":"relation","label":"co-mentioned with immunotherapy (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8a7a199d74aa040f57d16f92"},{"kind":"relation","label":"co-mentioned with etcamah (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d45029fe1bf1a0b1e69cfbc1"},{"kind":"relation","label":"co-mentioned with ctdna (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/991370b313124586cc108e83"},{"kind":"relation","label":"co-mentioned with ai (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5afb9223e418d870140d1640"},{"kind":"relation","label":"co-mentioned with astrazeneca (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b585c042111e7bee4adc3206"},{"kind":"relation","label":"co-mentioned with lung cancer (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/16b292d312c561aa11de5bb8"},{"kind":"relation","label":"co-mentioned with asco (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/93761e1fc655132c837556be"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/742d7293af168534ed95ef53","mcp":"traverse {\"id\":\"sb:e/742d7293af168534ed95ef53\"}","page":"/entity/her2-negative/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/742d7293af168534ed95ef53\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/742d7293af168534ed95ef53\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/742d7293af168534ed95ef53\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/742d7293af168534ed95ef53\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}